All In Biotech

Drug Trial Radar · NCT00361504

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

A One-Year, Randomized, Open-Label, Parallel-Arm, Phase 3 Long-Term Safety Trial, With Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR and Oxycodone CR in Subjects With Chronic Pain

Last checked: Nov 19, 2026Latest source record: Apr 29, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,123 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,123

Actual

Start

Nov 2006

Primary completion

Jul 2008

Study completion Jul 2008

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Grünenthal GmbH
First posted
Aug 8, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety profile of tapentadol (CG5503) PR at doses of 100 mg - 250 mg administered twice daily over a maximum one year period to patients with at least a 3-month history of low back pain, or pain caused by knee or hip osteoarthritis.

Conditions

  • Osteoarthritis, Hip
  • Osteoarthritis, Knee
  • Lower Back Pain
  • Pain

Interventions

  • Oxycodone CRDrug

    Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.

  • Tapentadol (CG5503) ERDrug

    Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAE)Time frame: 52 weeks

Locations

52 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Mesa, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Anaheim, California

  • Site not named

    Cudahy, California

  • Site not named

    Encinitas, California

  • Site not named

    San Diego, California

  • Site not named

    Westlake Village, California

  • Site not named

    Trumbull, Connecticut

  • Site not named

    Chiefland, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Oldsmar, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Cumming, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Perry, Georgia

  • Site not named

    Suwanee, Georgia

  • Site not named

    Woodstock, Georgia

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Prairie Village, Kansas

  • Site not named

    Topeka, Kansas

  • Site not named

    Paducah, Kentucky

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    Rockville, Maryland

  • Site not named

    Wellesley Hills, Massachusetts

  • Site not named

    Kalamazoo, Michigan

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Mamaroneck, New York

  • Site not named

    Williamsville, New York

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Kettering, Ohio

  • Site not named

    Medford, Oregon

  • Site not named

    Duncansville, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Greenville, South Carolina

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Roanoke, Virginia

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.